Market volatility has pushed a number of high-quality stocks lower. Here's how I'm thinking about this. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...

C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

Feb ⁠18 (Reuters) - ⁠Australia's CSL said on Wednesday it had entered into an exclusive ⁠licensing ⁠agreement with ⁠Eli Lilly and Co, granting it certain ⁠rights to develop ⁠and commercialise ...

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL is struggling to get the basics right. Although it takes time to turn around a sprawling business empire – as we’ll see at its results on Wednesday – it should be much easier to handle something ...

For the best part of a decade, the company was unimpeachable. But the sudden exit of chief executive Paul McKenzie underscores the new sense of chaos around the group. It’s all just so out of ...

SYDNEY--Australia-based pharmaceutical company CSL posted a steep decline in fiscal first-half profit, reflecting government policy changes, shifting public attitudes toward vaccines and one-off costs ...